Related references
Note: Only part of the references are listed.Intraperitoneal corticosteroids for recurrent ascites in patients with Fontan circulation: Initial clinical experience
Fred M. Wu et al.
JOURNAL OF CARDIAC SURGERY (2021)
Clinical risk factors and outcomes of massive ascites accumulation after discontinuation of peritoneal dialysis
Chien-Liang Chen et al.
RENAL FAILURE (2020)
Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options
Rajesh M. Jagirdar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
LENGTH OF TIME ON PERITONEAL DIALYSIS AND ENCAPSULATING PERITONEAL SCLEROSIS - POSITION PAPER FOR ISPD: 2017 UPDATE
Edwina A. Brown et al.
PERITONEAL DIALYSIS INTERNATIONAL (2017)
Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study
Mark R. Lambie et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Pilot Study of Intraperitoneal Administration of Triamcinolone Acetonide for Cancerous Ascites in Patients With End-Stage Gynecological Cancer
Tadahiro Shoji et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Encapsulating peritoneal sclerosis: the state of affairs
Mario R. Korte et al.
NATURE REVIEWS NEPHROLOGY (2011)
THE ROLE OF PERITONEAL LAVAGE AND THE PROGNOSTIC SIGNIFICANCE OF MESOTHELIAL CELL AREA IN PREVENTING ENCAPSULATING PERITONEAL SCLEROSIS
Tadashi Yamamoto et al.
PERITONEAL DIALYSIS INTERNATIONAL (2010)
Successful treatment of massive ascites with intraperitoneal administration of a steroid in a case of systemic lupus erythematosus
Q. G. Zhou et al.
LUPUS (2009)
The Use of Intraperitoneal Triamcinolone Acetonide for the Management of Recurrent Malignant Ascites in a Patient with Non-Hodgkin's Lymphoma
Rodric P. Jenkin et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2008)
A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites
JR Mackey et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2000)
Share Paper
